# Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
Canonical URL: https://biopharmsignal.com/news/CHRS/coherus-and-zumutor-biologics-announce-clinical-collaboration-to-evaluate-zm008-in-combination-with-loqtorzir-toripalimab-tpzi
Ticker: CHRS
Company: Coherus BioSciences, Inc.
Source: Coherus BioSciences, Inc.
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.coherus.com
## Summary

– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor – REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc.

## Article Body
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor – REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc.
## Recent Company News
- 2026-06-25 13:46 EST — [Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)](https://biopharmsignal.com/news/CHRS/coherus-and-zumutor-biologics-announce-clinical-collaboration-to-evaluate-zm008-in-combination-with-loqtorzir-toripalimab-tpzi) — Source: Coherus BioSciences, Inc.
- 2026-06-25 13:46 EST — [Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CHRS/coherus-oncology-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Coherus BioSciences, Inc.
- 2026-06-25 13:46 EST — [Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)](https://biopharmsignal.com/news/CHRS/coherus-oncology-announces-publication-in-molecular-cancer-therapeutics-highlighting-the-strong-pharmacology-of-investigational-ccr8-antibody-tagmokitug-chs-114) — Source: Coherus BioSciences, Inc.
- 2026-06-25 13:46 EST — [Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference](https://biopharmsignal.com/news/CHRS/coherus-management-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference) — Source: Coherus BioSciences, Inc.
- 2026-06-25 13:46 EST — [Coherus Oncology Announces Clinical Supply Agreement to Evaluate Tagmokitug in Combination with Pasritamig](https://biopharmsignal.com/news/CHRS/coherus-oncology-announces-clinical-supply-agreement-to-evaluate-tagmokitug-in-combination-with-pasritamig) — Source: Coherus BioSciences, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)